Researchers at The University of Texas Medical Branch in Galveston are putting the weight-loss drug tirzepatide under a different kind of microscope, launching a randomized study to see whether it can slow the pace of biological aging. The Moody Longevity Trial will enroll adults ages 55 to 70 and treat participants with the medication for 24 weeks, followed by a 12-week observation period to track biological-age biomarkers. Investigators plan to use DNA-methylation "epigenetic clocks" along with tests of mobility, mood and brain function to gauge whether any benefits stick around after the drug is stopped.
UTMB announced the study in late February and said the project is funded by the Moody Endowment. Geriatrician Dr. Thomas Blackwell described the goal as a chance to "add not just years to life but healthy years," according to UTMB News. A segment from KHOU this week highlighted the team’s focus on energy, mobility and brain health. The university says enrollment is open and the Clinical Research Center is currently accepting volunteers who meet the study criteria.
Why scientists are watching
Tirzepatide, which is marketed as Zepbound for chronic weight management, is a dual GIP and GLP-1 receptor agonist that has produced large weight-loss results in late-stage trials and is FDA-approved for that use, according to the FDA. Researchers say its broad metabolic effects, including reduced inflammation, improved insulin sensitivity and loss of visceral fat, make it a plausible candidate to influence biological-age markers, as discussed in Nature Reviews Endocrinology.
Early evidence and limits
There is already precedent for metabolic drugs nudging epigenetic clocks. A randomized, placebo-controlled 32-week trial of semaglutide showed reductions in several DNA-methylation age measures in a post-hoc analysis, according to a paper available on PubMed Central. Those findings helped spark interest in whether GLP-1-based therapies can change biological age, but experts caution that weight loss and reduced inflammation could account for much of the effect. Controlled trials like UTMB’s are needed to tease apart direct and indirect mechanisms.
Who can join and what to expect
UTMB’s eligibility criteria include ages 55 to 70, a body mass index of 30 or higher (or 27 with high blood pressure, diabetes or high cholesterol), stable medications and not using insulin, according to UTMB News. Interested volunteers are asked to contact the Clinical Research Center at (409) 772-1218 to learn more. Tirzepatide’s label lists common side effects such as nausea, diarrhea and vomiting, and it warns of rare but serious risks; the medication’s prescribing information is available from Eli Lilly.
UTMB researchers describe the Moody Longevity Trial as an early test of whether an already-available medicine can be repurposed to extend healthy years rather than just change body mass index, and they expect the trial’s biomarkers to help shape larger studies. Results will take time, and scientists emphasize that patients should not treat weight-loss prescriptions as proven "anti-aging" therapies until randomized trials like this one report their outcomes.
